Year: 2026

SHANGHAI, China and HEIDELBERG, Germany, and CAMBRIDGE, MA, USA, June 30, 2026 – Hengrui Pharma, a global pharmaceutical company focused on scientific and technological innovation, and Novaliq GmbH (“Novaliq”), a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on its unique EyeSol^® water-free platform technology, announce today that on June 23, 2026, the China National Medical Products Administration (NMPA) has approved Heng Yi^® (0.1% cyclosporine ophthalmic solution) for the treatment of patients with dry eye disease, aiming to increase tear secretion in patients with reduced tear production and improve the sign of the disease.

Novaliq Receives FDA IND Clearance to Advance NOV05 in a Phase II Clinical Trial in Non-infectious Anterior Uveitis

• Study could lead to first-ever topical steroid-free treatment for the inner eye disease non-infectious anterior uveitis (NIAU)
• The study builds on ocular pharmacokinetic models demonstrating delivery after topical application and on animal models of experimental uveitis demonstrating pharmacological effects
• Novaliq is expanding with this proof-of-concept study into retina and inner-eye diseases as targeted topical delivery of EyeSol^®-based drugs allowing to develop breakthrough therapies